Cancer: IMO-2055
IMO-2055, a TLR9 agonist, is in clinical development for the treatment of cancer.
Idera expects data from the following clinical trials with IMO-2055 to be available in the near term:
- A randomized Phase 2 clinical trial of IMO-2055 in combination with Erbitux(R) versus Erbitux alone as a second-line treatment in patients with recurrent and/or metastatic subcutaneous carcinoma of the head and neck (SCCHN).
- The design of the Phase 2 study provides for the enrollment of 104 patients, 52 in each of the two arms. Crossover of patients from Erbitux alone to IMO-2055 in combination with Erbitux is permitted under specified circumstances. The primary endpoint of the trial is progression-free survival. This study is fully enrolled and patient treatment and follow-up are ongoing.
- A Phase 1b clinical trial of IMO-2055 in combination with Tarceva(R) and Avastin(R) in patients with advanced non-small cell lung cancer (NSCLC).
- The NSCLC Phase 1b clinical trial evaluated four dose levels of IMO-2055 in combination with Tarceva(R) and Avastin(R). Thirty-six patients have been recruited in this trial and data analysis is ongoing.
- A Phase 1b clinical trial of IMO-2055 in combination with Erbitux(R) and FOLFIRI (5-fluorouracil/leucovorin/irinotecan) in patients with metastatic colorectal cancer (CRC).
- The CRC Phase 1b clinical trial evaluated three dose levels of IMO-2055 in combination with Erbitux(R) and FOLFIRI. Twenty-two patients have been recruited and data analysis is ongoing.
During December 2007 to November 2011, Idera collaborated with Merck KGaA for the research, development, and commercialization of Idera's TLR9 agonists, including IMO-2055, for the treatment of cancer. (Press Release). In November 2011, Idera regained global rights to IMO-2055 from Merck KGaA. Under Idera’s termination agreement with Merck KGaA, Merck KGaA will continue to conduct the ongoing Phase 2 trial in patients with SCCHN and Idera will have rights to the data, as well as to the data from Phase 1 trials conducted in other cancer indications. (Press Release)
